Expanded crop protection and chemical testing: For those committed to our planet’s sustainability and the welfare of humanity

We’ve been ramping up our product testing support at some of our European sites over the past few years to meet the needs of the rapidly growing crop protection and chemical industry. Now, we’re excited to announce a multimillion-dollar expansion at our Greenfield, Indiana campus in the U.S. that enhances your options even further to access more crop protection and chemical toxicology studies at a global scale.

Enhancing the Investigator Site Experience with Electronic Query Notification and Resolution (eQuery)

Investigator sites provide an essential connection between drug development sponsors and patients in clinical trials—and play a key role in producing high-quality data. To better support a site’s day-to-day study activities and make a difference for patient care, Labcorp Central Laboratory Services (CLS) is continually evaluating current practices and implementing ongoing process improvements.

Anti-Drug Antibody (ADA) positive controls generation against oligonucleotide therapeutics: Anti-Oligonucleotide antibody case study

Oligonucleotide therapeutics are generally single-stranded synthetic oligonucleotides with modifications in their structure to improve stability and PK properties. These therapeutics generally target RNA transcripts and reduce or modify the corresponding protein expression. Unlike most typical biologic drug classes such as monoclonal antibodies, the oligonucleotides are relatively small in size and contain fewer potential epitopes. In addition, the oligonucleotide therapeutics are delivered to immune restricted sites to remain locally confined.

Asia Pacific Expansion

4.7 billion. That’s the approximate population of Asia as of 2021. That number represents about 59 percent of the total world population. People are living longer and with that comes the demand for improved healthcare. With the Asia Pacific region accounting for about 15 percent of the drug development pipeline today, it’s no wonder that it is growing at a double-digit rate.

Connecting Expertise to Accelerate Lab Testing Innovations at Labcorp Central Laboratory Services

To help our clients shape the future of healthcare, Central Laboratory Services (CLS) at Labcorp Drug Development is continuously exploring new ways to enhance scientific expertise and anticipate lab testing needs.

Early development investments campaign magazine

Moving with urgency takes determination, ingenuity and passion. It also takes innovating where it matters most. The decision to invest more than $700 million in the past five years in Early Development all started with listening to you. These initiatives have spanned the entire globe with a mission to expand capacity, enhance technology and produce new ways of working to ensure you have the insight, speed and flexibility you need to advance your development programs and pursue answers to life-changing breakthroughs.

Fix, replace or augment: Key considerations for rescue or transition studies in medical device clinical trials.

Clinical trials are demanding, rigorous and time-sensitive. This is especially true for medical device development where the protocols, patient selection or surgical interventions may be highly specific. The demands on all parties – developer, Contract Research Organization (CRO), principal investigator, site staff and participants – are high, so it is little wonder that when a program is not meeting timelines, thoughts of “rescue” or “transition” may need to be considered.

Preclinical oncology renovation

According to a recent study from the American Cancer Society, over 19 million people were diagnosed with cancer in 2020. Cancer reaches every corner of the globe and touches way too many of our lives. And as the search for answers advances, all eyes are on oncology research and this growing drug development field full of new technology and treatment candidates.

Project Management Innovation: Collaboration without Boundaries

Innovation in project management systems is driving a future free of boundaries. Envision a platform that supports COVID-era virtual team collaboration, designed by operations people for operations people. A streamlined, holistic process that offers proactive insights into project health. An approach that makes managing portfolios and projects more intuitive, intelligent and supportive of risk management. We recently shared Labcorp Drug Development insights at the DIA conference; this blog summarizes the discussion.

A macro investment in micro science

The science behind the development of gene- and cell-based therapies is as granular as it gets. Research at this level of precision requires the latest technology, state-of-the-art facilities and expert staff to produce optimal outcomes. In order to schedule more of your cell and gene studies and help you create more therapies to help patients, we have invested an estimated $9.2 million into a comprehensive nonclinical expansion of our Madison, Wisconsin site set to be ready for your studies. This complements other companywide investments dedicated to cell and gene therapy capabilities and support.